Ed Amer represents private equity and venture capital firms, investors and private companies in a broad range of business and financing transactions. His practice focuses primarily on private equity acquisitions and dispositions, venture capital financings, mergers and acquisitions, start-up company counseling and general corporate representation. Prior to pursuing a career in law, Ed worked as a lighting technician in the motion picture industry.
•Advised ViraCor-IBT Laboratories, Inc., a premier specialty diagnostics laboratory, as general counsel and in its acquisition by Eurofins Scientific for a purchase price of approximately $255 million.
•Represented Ampersand Capital Partners in its investments in Blue Sky Biotech, a contract research organization; Modified Polymer Components, a manufacturer of polymer components for medical device OEMs; and ATS Labs, an antimicrobial testing services business.
•Represented Magellan Biosciences in the sale of its microbiology testing products division, TREK Diagnostic Systems, to Thermo Fischer Scientific.
•Represented a syndicate of investors, including Novartis Venture Fund and Venture Investors, in its investment in Euthymics Bioscience, a company developing novel medicines for major depressive disorder and ADHD.
•Represented IBT Laboratories in its merger with ViraCor Laboratories, forming in ViraCor-IBT Laboratories, a leading specialty diagnostics testing lab.
•Represented a syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in its investment in Radius Health.
•Represented Ampersand Capital Partners and SV Life Sciences in the acquisition of a controlling interest in CRI Worldwide, a leading provider of clinical research services to the pharmaceutical industry.
•Represented Novartis Venture Fund in its investment in drug development company Tokai Pharmaceuticals.
•Represented MPM Capital and New Enterprise Associates in their investment in Rhythm, a biotechnology company developing peptide therapeutics for metabolic diseases.
•Represented Open Ratings, a venture-backed on-line supply chain management company, in its acquisition by Dun & Bradstreet.
•Represented Ampersand Capital Partners in the leveraged buyout of K-TEK Corp., a leading global manufacturer of state-of-the-art level instrumentation for liquid and bulk solids detection.
•Represented K-TEK Corp. in its sale to ABB, the global power and automation technology group.
•General counsel to Ampersand Capital Partners.
•General counsel to Boston Heart Diagnostics Corporation.
•General counsel to Castlewood Surgical, Inc.
•General counsel to EnVivo Pharmaceuticals, Inc.
•General counsel to GnuBIO Inc.
•General counsel to Magellan Biosciences, Inc.
•General counsel to ViraCor-IBT Laboratories, Inc.
Edwards Wildman Team Represents ViraCor-IBT Laboratories in Its Sale to Eurofins Scientific
Our Business Law lawyers represented ViraCor-IBT Laboratories, Inc. in its sale to Eurofins Scientific for $255 million.
ATS Labs Acquisition of Microcheck
In December 2012 our lawyers represented ATS, Labs, Inc. in the asset purchase of Microcheck.
Novartis Bioventures Fourth Tranche, Series D-3 Preferred Stock Financing
In 2012 our Venture Capital lawyers in Boston represented Novartis Bioventures in the fourth tranche, series D-3 preferred stock financing of Tokai Pharmaceuticals.
Investment in Bioventus LLC by Ampersand Capital Partners
Edwards Wildman lawyers in Boston represented private equity firm Ampersand Capital Partners in the May 2012 investment in Bioventus LLC.
Acquisition of a Minority Interest in Pharmaceutical by Ampersand Capital Partners
An Edwards Wildman team in Boston represented the private equity firm Ampersand Capital Partners in the May 2012 acquisition of a minority interest in Eaton Veterinary Pharmaceuticals company.
$100,000,000 Senior Secured Credit Facility
In March 2012, a team of our lawyers represented United Recovery Systems and Enterprise Recovery Systems, as borrowers, in the senior secured credit facilities from The CIT Group/Business Credit Inc.
United Recovery Systems Purchased 100% of the Capital Stock of Enterprise Recovery Systems, Inc.
A team of our Mergers & Acquisitions, Tax, and Benefits and Compensation lawyers represented Audax Group and its portfolio company, United Recovery Systems, in the March 2012 purchase of 100% of the capital stock of Enterprise Recovery Systems, Inc.
Issuance of Stemline Therapeutics unsecured convertible notes
In 2012, our Securities lawyers represented New York City-based Stemline Therapeutics, Inc. in the issuance of unsecured convertible notes.
Vers Inc. Series A Financing
In December of 2011, a team of our Transactional lawyers represented Massachusetts based sound system designer Vers Inc. in the series A financing by Stockholm-based Ominor Capital.
Novartis Series D-3 Financing
In September 2011, our lawyers represented Novartis Bioventures in the $23,000,000 Series D-3 Financing for Tokai Pharmaceuticals, Inc.
MIT Enterprise Forum GET SMART
October 2, 2013 event
Edwards Wildman Sponsors LabCentral, First Large Scale Biotech-Capable Shared Lab Facility in Cambridge, Mass.
August 8, 2013
Edwards Wildman Advises ViraCor-IBT Laboratories, Inc. in Cylex Acquisition, Reports ABF Journal
April 11, 2013
Edwards Wildman New Partner Promotions Highlighted in Law360
March 27, 2013
Edwards Wildman Advises ViraCor-IBT Laboratories, Inc. in Cylex Acquisition
February 13, 2013
Edwards Wildman Elevates Three in Boston to Partner, Reports Massachusetts Lawyers Weekly
January 14, 2013
Edwards Wildman Admits Seven Lawyers to Partnership
January 2, 2013